<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403402</url>
  </required_header>
  <id_info>
    <org_study_id>CMDPROS1</org_study_id>
    <nct_id>NCT01403402</nct_id>
  </id_info>
  <brief_title>Congenital Muscle Disease Study of Patient and Family Reported Medical Information</brief_title>
  <acronym>CMDPROS</acronym>
  <official_title>Congenital Muscle Disease Patient and Proxy Reported Outcome Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cure CMD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cure CMD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a
      longitudinal 10 year study to identify and trend care parameters, adverse events in the
      congenital muscle diseases using the Congenital Muscle Disease International Registry (CMDIR)
      to acquire necessary data for adverse event calculations (intake survey and medical records
      curation). To support this study and become a participant, we ask that you register in the
      CMDIR. You can do this by visiting www.cmdir.org. There is no travel required.

      The registry includes affected individuals with congenital muscular dystrophy, congenital
      myopathy, and congenital myasthenic syndrome and registers through the late onset spectrum
      for these disease groups. The CMDIR was created to identify the global congenital muscle
      disease population for the purpose of raising awareness, standards of care, clinical trials
      and in the future a treatment or cure. Simply put, we will not be successful in finding a
      treatment or cure unless we know who the affected individuals are, what the diagnosis is and
      how the disease is affecting the individual.

      Registering in the CMDIR means that you will enter demographic information and complete an
      intake survey. We would then ask that you provide records regarding the diagnosis and
      treatment of CMD, including genetic testing, muscle biopsy, pulmonary function testing, sleep
      studies, clinic visit notes, and hospital discharge summaries.

      Study hypothesis:

        1. To use patient and proxy reported survey answers and medical reports to build a
           longitudinal care and outcomes database across the congenital muscle diseases.

        2. To generate congenital muscle disease subtype specific adverse event rates and correlate
           with key care parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a
      longitudinal 10 year observational study to identify care and trend key care parameters and
      adverse events in the congenital muscle diseases using the Congenital Muscle Disease
      International Registry (CMDIR). The CMDIR registers individuals with and without genetic
      confirmation who have been given a clinical diagnosis of congenital muscular dystrophy,
      congenital myopathy, and congenital myasthenic syndrome, or myofibrillar myopathy, through
      the limb girdle/late onset spectrum.

      Identifying care parameters and adverse events in the rare genetic neuromuscular diseases can
      be difficult. Care is fragmented, genetic confirmation may not be prioritized by the medical
      community or covered by medical insurance and patients are scattered globally with potential
      challenges aggregating data across centers. Natural history studies are currently being
      launched. However, potential biases to participation include recruitment of the less severely
      affected patients given difficulty traveling secondary to a medically fragile condition.
      There is currently no treatment for these conditions; though optimizing and standardizing
      care and care delivery can promote significant gains in quality of life and survival.
      Identifying disease specific care parameters and correlating those parameters with adverse
      event rates will not only contribute to the development of evidence based guidelines but
      inform clinically meaningful outcomes for future clinical trials.

      Study hypothesis:

        1. To use patient and proxy reported survey answers and medical reports to build a
           longitudinal care and outcomes database across the congenital muscle diseases.

        2. To generate congenital muscle disease subtype specific adverse event rates and correlate
           with key care parameters.

      Primary outcome is survival measured from date of birth to date of death. Primary outcome
      will be analyzed by congenital muscle disease subtype and maximal ambulatory status achieved.

      Secondary outcomes include disease specific adverse event rates including rates of
      hospitalization, rates of antibiotic use, rates of pulmonary infections, pneumothorax,
      atelectasis, aspiration and adverse complaints including bloating, constipation, chest pain,
      dyspnea assessed by a validated breathing assessment, vomiting and nausea and difficulty
      eating. Patient and proxy hospitalization, pneumothorax and atelectasis reports will be
      confirmed by obtaining hospital discharge summaries. Additional secondary outcomes include
      ejection fraction (relevance subtype specific), forced vital capacity in liters, weight,
      Rapid Eye Movement (REM) sleep apnea hypopnea index and mean oxygen saturation during REM and
      total sleep study, age, gender, type of treatment center location (national referral center,
      tertiary care hospital, community hospital), gastrostomy tube, total number of fractures and
      Tscore/Zscore of hip and spine on DEXA scans.

      Preliminary studies may focus on specific congenital muscle disease subtypes and use
      retrospective data collection through registry, survey monkey and telephone interviews to
      assess adverse event rates over last month and last year to limit recall bias. Prospective
      enrollment of same study participants over 12 months will assess monthly rates of adverse
      events and complaints. A preliminary study, CMD PROADE (Patient and Proxy Reported ADverse
      Event Rates) is planned in 2 congenital muscular dystrophy subtypes: Collagen 6 Myopathy and
      LAMA 2 Related CMD.

      De-identified data from CMDIR will be made available for IRB approved natural history studies
      in the congenital muscle diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Congenital Muscle Disease Patient and Proxy Reported Outcomes</measure>
    <time_frame>10 years</time_frame>
    <description>Correlation between genetic and biopsy findings and their relation to phenotypic and adverse event data.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Congenital Muscular Dystrophy (Including Unspecified/Undiagnosed)</condition>
  <condition>Dystroglycanopathy</condition>
  <condition>Congenital Fiber Type Disproportion</condition>
  <condition>Rigid Spine Muscular Dystrophy</condition>
  <condition>Congenital Myopathy (Including Unspecified/Undiagnosed)</condition>
  <condition>Collagen VI CMD (Ullrich CMD, Intermediate, Bethlem Myopathy)</condition>
  <condition>Laminin Alpha 2 Related Congenital Muscular Dystrophy</condition>
  <condition>LAMA2-CMD/Merosin Deficient/MDC1A</condition>
  <condition>Walker-Warburg Syndrome</condition>
  <condition>Muscle-Eye-Brain Disease</condition>
  <condition>Fukuyama/Fukutin Related Muscular Dystrophy</condition>
  <condition>Integrin Alpha 7 Deficiency</condition>
  <condition>Integrin Alpha 9 Deficiency</condition>
  <condition>LMNA-CMD/Lamin A/C/Laminopathy</condition>
  <condition>SEPN1-Related Myopathy</condition>
  <condition>Bethlem Myopathy</condition>
  <condition>Actin Aggregation Myopathy</condition>
  <condition>Cap Disease</condition>
  <condition>Central Core Disease</condition>
  <condition>Centronuclear Myopathy</condition>
  <condition>Core Rod Myopathy</condition>
  <condition>Hyaline Body Myopathy</condition>
  <condition>Multiminicore Myopathy</condition>
  <condition>Myotubular Myopathy</condition>
  <condition>Nemaline Myopathy</condition>
  <condition>Tubular Aggregate Myopathy</condition>
  <condition>Zebra Body Myopathy</condition>
  <condition>Reducing Body Myopathy</condition>
  <condition>Spheroid Body Myopathy</condition>
  <condition>LGMD1B (LMNA)</condition>
  <condition>LGMD1E (DES)</condition>
  <condition>LGMD2G (TCAP)</condition>
  <condition>LGMD2H (TRIM32)</condition>
  <condition>LGMD2I (FKRP)</condition>
  <condition>LGMD2J (TTN)</condition>
  <condition>LGMD2K (POMT1)</condition>
  <condition>LGMD2M (FKTN)</condition>
  <condition>LGMD2N (POMT2)</condition>
  <condition>LGMD2O (POMGnT1)</condition>
  <condition>LGMD2P (DAG1)</condition>
  <condition>LGMD2Q (PLEC1)</condition>
  <condition>LGMD2R (DES)</condition>
  <condition>LGMD2S (TRAPPC11)</condition>
  <condition>LGMD2T (GMPPB)</condition>
  <condition>LGMD2U (ISPD)</condition>
  <condition>LGMD2V (GAA)</condition>
  <condition>Ullrich Congenital Muscular Dystrophy</condition>
  <condition>Titinopathy</condition>
  <condition>Choline Kinase B Receptor</condition>
  <condition>Emery-Dreifuss Muscular Dystrophy</condition>
  <condition>RYR1 Related Myopathy</condition>
  <condition>SYNE1/Nesprin Related Muscular Dystrophy</condition>
  <condition>Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap)</condition>
  <condition>Congenital Myasthenic Syndrome</condition>
  <condition>Escobar Syndrome</condition>
  <condition>Myofibrillar Myopathy</condition>
  <condition>Malignant Hyperthermia</condition>
  <condition>Alpha-Dystroglycan Related Muscular Dystrophy (DAG1, DPM1, DPM2, DPM3, FKRP, FKTN)</condition>
  <condition>Alpha-Dystroglycan Related Muscular Dystrophy (GAA, ISPD, LARGE, POMT1, POMT2, POMGnT1)</condition>
  <condition>Alpha-Dystroglycan Related Muscular Dystrophy (Unspecified/Undiagnosed/Other)</condition>
  <arm_group>
    <arm_group_label>Congenital Muscle Disease</arm_group_label>
    <description>The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in CMDPROS will be selected from the CMD International Registry (CMDIR) based
        on the inclusion criteria above.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Alpha 7/Alpha 9 Integrin Related Myopathy Collagen VI Related Myopathy (Ullrich through
        Bethlem CMD) Alpha-Dystroglycan Related Muscular Dystrophy (Dystroglycanopathy, WWS, MEB,
        Fukuyama, FKRP, LGMD2I, LGMD2K, LGMD2M, LGMD2N, LGMD2O) Choline Kinase B Receptor
        Emery-Dreifuss Muscular Dystrophy (EDMD, LGMD1B, LMNA, Emerin, FHL1, SYNE1, SYNE2, TMEM43)
        LAMA2 Related Muscular Dystrophy (Laminin Alpha 2 related dystrophy/MDC1A/Merosin
        deficient) LMNA Related Muscular Dystrophy (Laminopathy/LaminA/C, L-CMD, Emery Dreifuss
        muscular dystrophy) RYR1 Related Myopathy (with dystrophic presentation, including
        Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) SEPN1 Related
        Myopathy (Rigid Spine Muscular Dystrophy/RSMD1, Congenital Fiber Type Disproportion,
        Mallory Weiss Body Desmin, Multi-minicore Myopathy) SYNE1 (Nesprin Related Muscular
        Dystrophy) Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap) Congenital Muscular
        Dystrophy Not Otherwise Specified (including Merosin Positive) Titin Related LGMD/CMD,
        LGMD2J Actin Aggregation Myopathy Cap Disease Central Core Disease (including Malignant
        Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Centronuclear Myopathy
        (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis)
        Congenital Fiber Type Disproportion (including Malignant Hyperthermia, Exertional Myalgia
        with or without Rhabdomyolysis) Core Rod Myopathy Hyaline Body Myopathy Multiminicore
        Myopathy Myotubular Myopathy Nemaline Myopathy Reducing Body Myopathy RYR1 Related Myopathy
        (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis)
        Spheroid Body Myopathy Titin Related Myopathy, Titin Related Dialated Cardiomyopathy,
        LGMD2J Tubular Aggregate Myopathy Zebra Body Disease Myopathy Congenital Myopathy Not
        Otherwise Specified Congenital Myasthenic Syndrome Escobar Syndrome Myofibrillar Myopathy

        Exclusion Criteria:

        Charcot Marie Tooth Duchenne/Becker Muscular Dystrophy Facioscapulohumeral Dystrophy/FSHD
        Kennedy's Disease LGMD-1A (TTID) LGMD-1C (CAV3, Caveloin 3, Caveolinopathy, LQT9, VIP21)
        LGMD-1D (7q) LGMD-1E (6q23) LGMD-1F (7q32.1-q32.2) LGMD-1G (4q21) LGMD-2A
        (CAPN3/Calpainopathy) LGMD-2B (DYSF/Dysferlinopathy/Miyoshi Myopathy) LGMD-2C (SGCG)
        LGMD-2D (SGCA) LGMD-2E (SGCB) LGMD-2F (SGCD) LGMD-2L (AN05/Anoctamin 5) Lipodystrophy
        Myotonic Dystrophy Oculopharyngeal Muscular Dystrophy Spinal Muscular Atrophy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Dziewczapolski, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CureCMD, CMDIR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Rutkowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cure CMD, CMDIR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Alvarez</last_name>
    <email>counselor@cmdir.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Congenital Muscle Disease International Registry (www.cmdir.org)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Alvarez</last_name>
      <email>counselor@cmdir.org</email>
    </contact>
    <investigator>
      <last_name>Gustavo Dziewczapolski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Rutkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bönnemann CG, Rutkowski A, Mercuri E, Muntoni F; CMD Outcomes Consortium. 173rd ENMC International Workshop: congenital muscular dystrophy outcome measures 5-7 March 2010, Naarden, The Netherlands. Neuromuscul Disord. 2011 Jul;21(7):513-22. doi: 10.1016/j.nmd.2011.04.004. Epub 2011 Jun 8.</citation>
    <PMID>21641800</PMID>
  </reference>
  <reference>
    <citation>Wang CH, Bonnemann CG, Rutkowski A, Sejersen T, Bellini J, Battista V, Florence JM, Schara U, Schuler PM, Wahbi K, Aloysius A, Bash RO, Béroud C, Bertini E, Bushby K, Cohn RD, Connolly AM, Deconinck N, Desguerre I, Eagle M, Estournet-Mathiaud B, Ferreiro A, Fujak A, Goemans N, Iannaccone ST, Jouinot P, Main M, Melacini P, Mueller-Felber W, Muntoni F, Nelson LL, Rahbek J, Quijano-Roy S, Sewry C, Storhaug K, Simonds A, Tseng B, Vajsar J, Vianello A, Zeller R; International Standard of Care Committee for Congenital Muscular Dystrophy. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol. 2010 Dec;25(12):1559-81. doi: 10.1177/0883073810381924. Epub 2010 Nov 15. Review.</citation>
    <PMID>21078917</PMID>
  </reference>
  <reference>
    <citation>Sparks SE, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP, Pegoraro E. Congenital Muscular Dystrophy Overview. 2001 Jan 22 [updated 2012 Aug 23]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from http://www.ncbi.nlm.nih.gov/books/NBK1291/</citation>
    <PMID>20301468</PMID>
  </reference>
  <reference>
    <citation>Geranmayeh F, Clement E, Feng LH, Sewry C, Pagan J, Mein R, Abbs S, Brueton L, Childs AM, Jungbluth H, De Goede CG, Lynch B, Lin JP, Chow G, Sousa Cd, O'Mahony O, Majumdar A, Straub V, Bushby K, Muntoni F. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord. 2010 Apr;20(4):241-50. doi: 10.1016/j.nmd.2010.02.001. Epub 2010 Mar 6.</citation>
    <PMID>20207543</PMID>
  </reference>
  <reference>
    <citation>Sewry CA, Jimenez-Mallebrera C, Muntoni F. Congenital myopathies. Curr Opin Neurol. 2008 Oct;21(5):569-75. doi: 10.1097/WCO.0b013e32830f93c7. Review.</citation>
    <PMID>18769251</PMID>
  </reference>
  <reference>
    <citation>Klein A, Clement E, Mercuri E, Muntoni F. Differential diagnosis of congenital muscular dystrophies. Eur J Paediatr Neurol. 2008 Sep;12(5):371-7. doi: 10.1016/j.ejpn.2007.10.002. Epub 2007 Dec 3.</citation>
    <PMID>18588847</PMID>
  </reference>
  <reference>
    <citation>Godfrey C, Clement E, Mein R, Brockington M, Smith J, Talim B, Straub V, Robb S, Quinlivan R, Feng L, Jimenez-Mallebrera C, Mercuri E, Manzur AY, Kinali M, Torelli S, Brown SC, Sewry CA, Bushby K, Topaloglu H, North K, Abbs S, Muntoni F. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain. 2007 Oct;130(Pt 10):2725-35. Epub 2007 Sep 18.</citation>
    <PMID>17878207</PMID>
  </reference>
  <reference>
    <citation>Ramelli GP, Aloysius A, King C, Davis T, Muntoni F. Gastrostomy placement in paediatric patients with neuromuscular disorders: indications and outcome. Dev Med Child Neurol. 2007 May;49(5):367-71.</citation>
    <PMID>17489811</PMID>
  </reference>
  <reference>
    <citation>Mellies U, Dohna-Schwake C, Voit T. Respiratory function assessment and intervention in neuromuscular disorders. Curr Opin Neurol. 2005 Oct;18(5):543-7. Review.</citation>
    <PMID>16155437</PMID>
  </reference>
  <reference>
    <citation>Takaso M, Nakazawa T, Imura T, Okada T, Ueno M, Saito W, Takahashi K, Yamazaki M, Ohtori S. Surgical correction of spinal deformity in patients with congenital muscular dystrophy. J Orthop Sci. 2010 Jul;15(4):493-501. doi: 10.1007/s00776-010-1486-9. Epub 2010 Aug 19.</citation>
    <PMID>20721717</PMID>
  </reference>
  <reference>
    <citation>Schara U, Kress W, Bönnemann CG, Breitbach-Faller N, Korenke CG, Schreiber G, Stoetter M, Ferreiro A, von der Hagen M. The phenotype and long-term follow-up in 11 patients with juvenile selenoprotein N1-related myopathy. Eur J Paediatr Neurol. 2008 May;12(3):224-30. Epub 2007 Oct 22.</citation>
    <PMID>17951086</PMID>
  </reference>
  <reference>
    <citation>Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Aloysius A, Clement E, North B, Manzur AY, Robb SA, Mercuri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. Neurology. 2009 Jul 7;73(1):25-31. doi: 10.1212/WNL.0b013e3181aae851.</citation>
    <PMID>19564581</PMID>
  </reference>
  <reference>
    <citation>van den Engel-Hoek L, Erasmus CE, de Swart BJ, Sie LT, de Groot IJ. Neonatal swallowing assessment and practical recommendations for oral feeding in a girl with a severe congenital myopathy. J Child Neurol. 2011 Aug;26(8):1041-4. doi: 10.1177/0883073811402071. Epub 2011 May 3.</citation>
    <PMID>21540369</PMID>
  </reference>
  <reference>
    <citation>Saito Y, Komaki H, Hattori A, Takeuchi F, Sasaki M, Kawabata K, Mitsuhashi S, Tominaga K, Hayashi YK, Nowak KJ, Laing NG, Nonaka I, Nishino I. Extramuscular manifestations in children with severe congenital myopathy due to ACTA1 gene mutations. Neuromuscul Disord. 2011 Jul;21(7):489-93. doi: 10.1016/j.nmd.2011.03.004. Epub 2011 Apr 21.</citation>
    <PMID>21514153</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital Muscular Dystrophy</keyword>
  <keyword>Congenital Myopathy</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
    <mesh_term>Myopathies, Structural, Congenital</mesh_term>
    <mesh_term>Myasthenic Syndromes, Congenital</mesh_term>
    <mesh_term>Malignant Hyperthermia</mesh_term>
    <mesh_term>Contracture</mesh_term>
    <mesh_term>Myopathies, Nemaline</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Myopathy, Central Core</mesh_term>
    <mesh_term>Walker-Warburg Syndrome</mesh_term>
    <mesh_term>Muscular Dystrophy, Emery-Dreifuss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

